Full-Time
Director Advertising and Promotional Compliance
AstraZeneca
10,001+ employees
Global pharmaceutical company developing prescription medicines
Compensation Overview
$193.3k - $289.9k/yr
Boston, MA, USA
Hybrid
Three days per week in the office required.
 Legal & Compliance (1) |
|---|
Get referred to AstraZeneca
Find people who can refer or advise you
- Bachelor’s degree
- 7+ years pharmaceutical industry in regulatory affairs and/or advertising and promotion
- Expertise in US advertising and promotional regulations and the current regulatory environment
- Experience communicating and negotiating directly with OPDP and/or APLB
- Experience leading a team or experience having direct reports
- Experience with global standards for advertising and promotional compliance
- Excellent written and verbal skills and strong interpersonal skills
- Consistent track record practicing sound judgment as it relates to risk assessment
- Knowledgeable on industry compliance requirements and non-compliance examples and trends
- Demonstrated ability to influence others and foster team collaboration
- Strong interpersonal, communication, and leadership skills!
- Reviewing US promotional, non-promotional, and scientific material, attending review meetings and providing regulatory guidance to the cross-functional team responsible for ensuring adherence to compliance standards and FDA regulations pertaining to prescription drug advertising, promotion, and communication as applicable
- Serving as primary contact for communications with the Office of Prescription Drug Promotion (OPDP) and/or Advertising and Promotional Labeling Branch (APLB) for assigned products
- Developing processes and procedures relevant to the creation, review and approval of advertising and promotional materials: Developing best practices, working instructions and/or SOPs to establish standards and consistency across company brands
- As needed, providing training support within Alexion on requirements for prescription drug promotion including, but not limited to, sales training and compliance training in preparation for scientific congresses and conferences
- Advising product development teams on advertising and promotion issues to facilitate the strategic development of new products
- Maintaining regulatory expertise in product promotion and compliance by keeping current with issued FDA enforcement actions and through attendance of relevant conferences and/or seminars. Communicate new regulatory standards pertaining to prescription drug promotion to brand teams and management, as appropriate
- Participating in and supporting ongoing key initiatives including the development, implementation, and continued improvement of promotional review process
- Supporting and mentoring ad/promo colleagues
- JD, PharmD or master’s degree preferred
AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Get referred to AstraZeneca
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Zegfrovy adds $83.4M revenue with 85% growth and first-line potential.
- TQC3721 respiratory deal expands COPD pipeline with up to $1.9B value.
- Rare Disease Centre of Excellence in Abu Dhabi accelerates regional diagnostics.
What critics are saying
- Wainua ATTR-CM Phase III failure blocks $2B+ revenue and cedes market.
- Zegfrovy severe lung disease risk threatens first-line label and reimbursement.
- TQC3721 China Phase III failure could trigger $1.9B milestone clawback.
What makes AstraZeneca unique
- Dual UK-Sweden heritage unifies deep R&D with global commercial scale.
- Leading EGFR-mutated lung cancer franchise anchored by Tagrisso dominance.
- First oral chemo-free monotherapy for EGFR exon 20 via Zegfrovy licensing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 6%BIO Asia-Taiwan 2026 Regional Collaboration Forum: closing the final gap to establish Taiwan as an international biotech hub. 18 July, 2026 The BIO Asia-Taiwan Regional Collaboration Forum was held on the 16th of July, part of BIO Asia-Taiwan 2026, held at the Nangang Exhibition Center, TaiNEX 1 & 2, Taipei, Taiwan, and brought together representatives from both established and emerging biotech nations to discuss how strengthened regional cooperation can accelerate the advancement of biotechnology across Asia and drive global innovation. Speakers agreed that biotechnology is a strategic priority requiring regional collaboration rather than competition. The forum concluded with a resolution to establish a regional working group to share best practices, publish a white paper, and develop joint recommendations on investment, startup incubation, clinical trials, supply chain resilience, and policy coordination. The main conference forum opened with keynote speeches from this year's BIO Asia Award recipients, including Individual Award winner Professor Masatoshi Hagiwara of Kyoto University, and Organization Award winner AstraZeneca. A leading expert in translational medicine, Professor Hagiwara has advanced RNA splicing and transcriptomics-based drug discovery, laying key foundations for RNA-targeting small-molecule therapeutics, and has actively promoted the development of the Japanese Society of Chemical Biology. He shared his experiences in translating innovative research into clinical applications. Mark Little, General Manager of AstraZeneca Taiwan, shared the company's experience in rapidly developing COVID-19 vaccines during the pandemic and supplying them globally through the COVAX initiative. He also highlighted AstraZeneca's post-pandemic efforts to deliver advanced treatments and diagnostics for lung cancer and chronic disease patients across Asia. Global competition intensifying, collaboration increasingly important Helen Chen, head of Asia Healthcare at global strategy consulting firm L.E.K. Consulting delivered a keynote address exploring strategies for regional collaboration and ecosystem development. Chen noted that Asian countries each have distinct strengths, with success depending on strong ecosystems supported by capital, talent, regulations, and infrastructure. South Korea leads in bio-manufacturing, Singapore has built a comprehensive ecosystem, and Shanghai has gained recognition through its Zhangjiang Pharma Valley, CDMO/CRO talent development, and multinational R&D centers. Taiwan has established a solid foundation but needs greater involvement from global integrators and international capital to accelerate growth. Chen noted that life science ecosystems across Asia remain smaller than those in the U.S. and Europe. While Taiwan has made strong early investments through public funding, it still faces gaps in talent, industry experience, and internationalization, and must overcome challenges in advancing scientific discoveries into late-stage clinical development and on to global commercialization. Ming-Hsiu Hsieh of the Taiwan Stock Exchange delivered a presentation titled "Empowering the Future of Biotech via Taiwan's Capital Market," noting that Taiwan's securities market is now the world's fifth-largest by scale, with the biotech sector largely driven by small and medium-sized enterprises. He said that countries are competing to attract capital and talent through IPO listings, R&D centers, and clinical trial hubs. To attract biotech companies, the Taiwan Stock Exchange launched initiatives such as the Innovation Board, providing policy support and lowering listing requirements for companies with innovative technologies. The Netherlands representative highlighted the "Quadruple Helix" collaboration model, which connects government, academia, industry, and patient groups. Home to the European Medicines Agency (EMA), the Netherlands is a European logistics and life sciences hub and provides funding support for international research collaborations. The Australian representative highlighted the country's leadership in regional clinical trials, combining strengths in other high-tech areas such as AI while advancing cross-border data sharing. The Canadian representative highlighted achievements in AI-driven drug discovery, precision medicine, and biologics. The Hong Kong representative noted that biotechnology is a key priority in the government's development strategy, and invited Taiwanese and Asian biotech companies to use Hong Kong as a platform for fundraising and accessing global markets. The Indian representative noted that India is shifting from a focus on global volume supply to value-driven supply. Its 2047 vision emphasizes biopharmaceuticals, production-linked incentives, and AI-enabled medical devices, while highlighting opportunities for collaboration with Taiwan. The Japanese representative noted that while Japan is home to many large pharmaceutical companies, numerous small and mid-sized biotech firms also require funding and strategic partners. Through international collaboration, Japan aims to connect these companies with global resources and partnership opportunities. The Korean representative emphasized open innovation and Korea's R&D efficiency, calling for Asian countries to establish cross-border VC syndicates to support small and mid-sized biotech companies. The Singapore representative noted that the country has strong capabilities in basic research and pharmaceutical manufacturing, while Taiwan's CDMO facilities could complement its GMP clinical capabilities, and collaborate on research on Asian-prevalent diseases. The representative from the US-based Biotechnology Innovation Organization (BIO) shared insights on the evolving political and policy landscape facing the U.S. biotechnology industry. Emphasizing "America First, but not alone," the representative called for global partnerships to build resilient supply chains and accelerate innovation. Newly elected International Council of Biotechnology Associations (ICBA) Chair and Taiwan Bio Industry Organization (Taiwan BIO) Secretary-General Wallace Lin shared ICBA's key priorities for 2026-2027, including intellectual property protection, AI applications, ecosystem development, support for innovative SMEs, new financing models, and regulatory modernization. He highlighted Taiwan's strengths, including the government's "Healthy Taiwan" initiative, US$1.5 billion in infrastructure investment, advances in cell and gene therapy, and the integration of biotechnology with semiconductor capabilities through "Tech Bio." BIO Asia-Taiwan Chairman Johnsee Lee stated that the Regional Collaboration Forum aims to develop proposals on key priorities, including cross-border venture capital, startup incubation, supply chain resilience, and regulatory harmonization. The forum intends to facilitate exchanges of best practices among countries, publish a white paper, and sign memoranda of understanding to advance practical cooperation initiatives. www.bioasiataiwan.com Media contacts: Dave Silver | 0931-051009 | Line ID: davesilver9619 | [email protected] Daisy Tsai | 0933-139647 | Line ID: daisy222
Weiguo Zhai settles SEC insider trading charges over Icosavax stock. Weiguo Zhai, a former senior director at AstraZeneca Pharmaceuticals, has agreed to settle SEC insider trading charges related to trading in Icosavax Inc. stock ahead of the company's acquisition by AstraZeneca. The SEC filed the settled complaint on July 8, 2026, in the District of Maryland, alleging Zhai misappropriated confidential information and realized $10,006 in illicit profits. What happened. The SEC charged Zhai with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, the antifraud provisions that prohibit trading on material nonpublic information. The commission also charged him with violating Section 14(e) and Rule 14e-3, which specifically address trading in the context of tender offers. The complaint alleged that Zhai was on AstraZeneca's due diligence team evaluating the anticipated acquisition of Icosavax Inc. through a tender offer. He allegedly misappropriated confidential information about the planned transaction and traded on that nonpublic information for personal benefit. Key facts. | Item | Details | | Defendant | Weiguo Zhai, age 56, Potomac, MD | | Employer | AstraZeneca Pharmaceuticals LP | | Target company | Icosavax Inc. | | Shares purchased (own account) | 1,000 shares at $11.04 | | Shares purchased (wife's account) | 1,000 shares at $10.54 | | Illicit profits | $10,006 | | Disgorgement | $10,006 | | Prejudgment interest | $1,535 | | Civil penalty | $10,006 | | Total settlement | $21,547 | | Stock price increase post-announcement | 49.48% | Icosavax impact. Zhai worked at AstraZeneca Pharmaceuticals LP, a wholly owned subsidiary of AstraZeneca PLC, from July 2020 to May 2024. He was based in the Gaithersburg, Maryland office and served as a senior director for research and development. The SEC said Zhai was assigned to AstraZeneca's due diligence team evaluating the anticipated acquisition of Icosavax, a biopharmaceutical company focused on vaccine development. The acquisition was announced on December 12, 2023, with a reported deal value of approximately $800 million. According to the complaint, Zhai purchased 1,000 shares of Icosavax in his own brokerage account at $11.04 per share and another 1,000 shares in his wife's account at $10.54 per share. After the acquisition announcement caused Icosavax stock to rise approximately 49.48%, Zhai sold the shares on December 12 and 13, 2023, realizing aggregate illicit profits of $10,006. What investors should do. Insider trading undermines market integrity and harms ordinary investors who trade without access to material nonpublic information. The SEC's charges against Zhai illustrate how employees with access to confidential deal information can exploit that advantage for personal gain. The SEC emphasized that Zhai consented to the entry of a final judgment permanently enjoining him from future violations of the charged provisions. The settlement is subject to court approval and was reached without Zhai admitting or denying the allegations. How to recover your losses. Investors who traded Icosavax stock during the relevant period may wish to review their account records for potential claims. While the SEC's enforcement action addresses the illegal trading itself, private securities litigation and FINRA arbitration may provide avenues for affected investors to seek compensation. Documenting the timing of trades, the prices paid, and any information known at the time of trading is essential for evaluating potential recovery options. Investors should consult a qualified securities attorney to assess their specific circumstances. Haselkorn & Thibaut fights for investor recovery. Haselkorn & Thibaut is a securities law firm founded by former Wall Street defense attorneys who shifted their practice to represent investors. The firm has recovered over $520 million for clients in securities matters and maintains a 98 percent success rate in resolved nontraded REIT cases. Attorneys are AV Preeminent rated through Martindale-Hubbell, designated as Super Lawyers, and hold a 5.0-star client review average. The firm operates on a contingency basis - no recovery, no fee. Contact haselkorn & Thibaut today. Time matters in recovery cases. The earlier you act, the stronger your position. The firm offers a free case evaluation to assess your losses, review your account history, and explain your options under arbitration or settlement. Offices in Florida, New York, Arizona, Texas, and North Carolina. Former Wall Street defense attorneys with 95+ years of combined experience. No recovery, no fee. This article is for informational purposes only and does not constitute legal advice. Investors should consult a qualified securities attorney to discuss their specific situation. AlphaBetaStock.com is a news and market research website. Its team provides commentary and analysis on a wide range of investment news topics, they have over 20 years of combined financial industry experience and a broad range of educational backgrounds and advanced degrees from around the globe.
AstraZeneca's Bet on the Future of COPD Treatment. A $200 million upfront payment, with milestones potentially taking the deal's total value to $1.9 billion, gives AstraZeneca exclusive rights to develop and commercialise an experimental COPD treatment outside China. More importantly, it highlights a broader shift in how Big Pharma is sourcing innovation. AstraZeneca has signed a licensing agreement with Chia Tai Tianqing Pharmaceutical Group (part of Sino Biopharmaceutical) for a molecule called TQC3721, an experimental treatment for Chronic Obstructive Pulmonary Disease (COPD). With a $200 million upfront payment, and further development, regulatory and sales milestones that could take the total deal value to $1.9 billion, AstraZeneca has gained the rights to develop and commercialise the drug globally, excluding China. The agreement highlights not only the search for new treatments for one of the world's most common respiratory diseases, but also the changing landscape of pharmaceutical innovation.[1] Key deal terms: Upfront payment $200m · Total potential value up to $1.9bn · Rights granted: global, excluding China · Development stage: Phase IIb COPD data reported; nebulised formulation in Phase III in China What is TQC3721? TQC3721 is an investigational COPD medicine that works as a dual PDE3 and PDE4 inhibitor.[2] PDE3 inhibition helps relax the smooth muscles in the airways, improving airflow and making breathing easier. PDE4 inhibition reduces inflammation and mucus production within the lungs, two key contributors to COPD symptoms. COPD is a progressive, long-term lung disease that causes breathing difficulties. It includes conditions such as emphysema, where the air sacs in the lungs become damaged, and chronic bronchitis, where the airways become inflamed and produce excess mucus. The main causes include long-term exposure to lung irritants such as cigarette smoke and chemical fumes.[3] COPD affects hundreds of millions of people worldwide and remains one of the leading causes of death globally.[4] TQC3721 has demonstrated encouraging Phase II results, but it still requires successful Phase III trials and regulatory approval before it can reach patients.[5] Why would AstraZeneca pay before approval? Why would AstraZeneca commit billions to a medicine that has not yet reached the market? The answer lies in the difficulty of drug development. Creating new medicines is expensive, time-consuming and highly uncertain, with many potential treatments failing before reaching approval. Rather than discovering every drug internally, pharmaceutical companies are increasingly partnering with smaller biotechnology firms that have already developed promising candidates. Once a molecule shows potential in early clinical trials, larger companies can license the rights and continue development, reducing the time and scientific risk involved. AstraZeneca's deal for TQC3721 reflects this broader strategy: acquiring access to promising innovation before competitors do. What role does China play? China has rapidly transformed from being primarily a manufacturing hub for medicines into one of the world's fastest-growing centres for biotechnology innovation. Some reports estimate that Chinese biotechnology companies now contribute a significant proportion of the global innovative drug pipeline, driven by substantial investment, government support and an influx of scientific talent.[6] China also has a major advantage in clinical research: its large population allows pharmaceutical companies to recruit patients for clinical trials at significant scale. This can help accelerate the process of testing new medicines compared with smaller markets. Historically, global pharmaceutical innovation was concentrated in established biotechnology hubs such as Boston, San Francisco and Cambridge (UK). Today, however, companies are increasingly looking towards Shanghai, Beijing and Suzhou: not simply as commercial markets, but as sources of novel therapies. China is no longer just a place to sell medicines: it's becoming a place to find them. A changing market. The way pharmaceutical companies discover new medicines is changing. Instead of developing every drug internally, companies are increasingly partnering with smaller biotechnology firms that have already created promising treatments. These deals allow Big Pharma to access new medicines faster, reduce the risks associated with research and development, and strengthen future drug pipelines. AstraZeneca's agreement for TQC3721 reflects this wider shift in how the pharmaceutical industry is finding its next generation of therapies. Final thoughts. AstraZeneca's deal extends beyond TQC3721 itself. It highlights a wider transformation in healthcare: the next generation of medicines may emerge from biotech ecosystems across the world, not only from traditional centres of innovation. The challenge is no longer simply discovering new drugs: it is knowing where to look.
Brian Cox returns to Oldham for science education event. If there's one person who can encourage young people in Oldham to study science, it's Professor Brian Cox. The Chadderton-born physicist and broadcaster was back in his home town on Monday, meeting with school pupils and launching a new partnership helping to bring more science opportunities to local primary schools. He joined a panel discussion at the event centre at Boundary Park, where Oldham Athletic Community Trust announced their plans to team up with leading biopharmaceutical company AstraZeneca for the Active Science in Schools Project. Professor Brian Cox joins a panel discussion at Boundary Park event centre (Image: The Oldham Times) Professor Cox was joined by the Greater Science Share founder Dr Lynne Bianchi, AstraZeneca UK chairman Shaun Grady, Oldham Council's director of growth James Kington, and Oldham Athletic Community Trust CEO Sandy Mitchell. The event was co-hosted by Latics CEO Darren Royle. Ahead of the panel discussion, Professor Cox spent the afternoon with primary school pupils, who got a chance to ask the physicist some of their most pressing science questions. He said that there was "no shortage of talent" in Oldham and remarked on how impressed he was by their curiosity and degree-level questions, even encouraging some of them to apply for his University of Manchester courses in the future. Professor Brian Cox said there is "no shortage of talent" in Oldham (Image: The Oldham Times) Speaking in support of the Active Science in Schools Project rollout in Oldham, he added: "You have a place here which is well connected. You look out there and there's the motorway, there's the railway. It's very close to Manchester and the big universities there. "But you also have this untapped potential: you have space, you have development sites. You've got these incredibly talented, curious young people waiting to do wonderful things. "It seems to me that the foundations are here, the raw materials are here. And, as you said, it therefore makes sense to invest." When it comes to inspiring young people to take up STEM subjects, he said it was his hometown Oldham that helped foster his interest in astronomy. As a child, he would head to Chadderton Heights, where night skies are darker and further away from city lights. He added: "That's a real resource. I don't think my imagination would have been captured by astronomy if I'd grown up in a city centre, but I grew up in Chadderton, which is close enough to the night sky." Mayor Pam Byrne joins the panellists for a photo. (Image: The Oldham Times) What is the Active Science in Schools Project? Mr Mitchell explained to the crowd that the Active Science project, organised through the AstraZeneca Partnership, is a six-week programme that will be delivered in Oldham primary schools starting the next academic year. He said: "For us, it's about addressing a need within Oldham schools. How can we enhance what's already going on? "There's some fantastic work already happening, but how can this programme help to enhance that work and reach some of those young people who maybe aren't quite getting the opportunities we'd like them to have in Oldham?" Mr Kington hopes that by leading more young people towards science subjects, it will help "keep Oldham talent in Oldham". He said: "It's just about giving the best for the young people involved. And the better and more skilled our workforce is, the better our businesses will do. "The better our workforce and businesses do, the more jobs will come to Oldham, because people will look for that skilled workforce."
Zymeworks to buy Theravance for $929 million in push to expand beyond cancer. By Thomson Reuters Jun 29, 2026 | 6:13 AM June 29 (Reuters) - Zymeworks said on Monday it will acquire Theravance Biopharma for $929 million in cash, marking the oncology-focused drugmaker's entry into the highly competitive respiratory disease segment. The deal gives Zymeworks access to Theravance's FDA-approved drug Yupelri, a once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD), putting it in competition with major drugmakers that dominate the segment, including GSK, AstraZeneca and Boehringer Ingelheim. COPD is a progressive lung disease that obstructs airflow and makes breathing difficult. Under the agreement, Zymeworks will buy all outstanding Theravance shares for $17 each, implying an about 3.6% discount to the stock's last close on Friday. Zymeworks said Theravance has a 35% net profit share in Yupelri in the U.S., which is marketed in the country through a collaboration with Viatris. In 2025, Yupelri's U.S. net sales were $266.6 million, up 12% from 2024. U.S. net sales rose 7% to $62.4 million in the first quarter of 2026. The acquisition is expected to provide near-term cash flow following the deal's close, which is expected in the second half of 2026, Zymeworks said. Theravance had said earlier this year it was exploring strategic alternatives, including a potential sale, after its experimental drug ampreloxetine for a rare disorder failed a late-stage trial, prompting a restructuring that could affect about half of its workforce. Zymeworks said it will consider monetizing acquired assets, including ampreloxetine, with any proceeds from a potential ampreloxetine deal to be split 20% for Zymeworks and 80% for Theravance shareholders. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda)